The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases

Jaume Alijotas-Reig, Enrique Esteve-Valverde, Raquel Ferrer-Oliveras, Luis Sáez-Comet, Elmina Lefkou, Arsène Mekinian, Cristina Belizna, Amelia Ruffatti, Angela Tincani, Luca Marozio, Gerard Espinosa, Ricard Cervera, Roberto Ríos-Garcés, Sara De Carolis, Omar Latino, Elisa Llurba, Cecilia Beatrice Chighizola, Maria Gerosa, Vittorio Pengo, Krista LundelinPatrizia Rovere-Querini, Valentina Canti, Karoline Mayer-Pickel, Tatiana Reshetnyak, Ariela Hoxha, Sara Tabacco, Ldjumila Stojanovich, Vassiliki Gogou, Aikaterini Varoudis, Anna Arnau, Domingo Ruiz-Hidalgo, Jaume Trapé, Laia Sos, Carlotta Stoppani, Anna Martí-Cañamares, Inmaculada Farran-Codina

Risultato della ricerca: Contributo in rivistaArticolo in rivista

27 Citazioni (Scopus)


Aim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a cohort of 1000 women with obstetric antiphospholipid syndrome (OAPS). Methods: The European Registry of OAPS became a registry within the framework of the European Forum on Antiphospholipid Antibody projects and was placed on a website in June 2010. Thirty hospitals throughout Europe have collaborated to carry out this registry. Cases with obstetric complaints related to antiphospholipid antibodies (aPL) who tested positive for aPL at least twice were included prospectively and retrospectively. The seven-year survey results are reported. Results: 1000 women with 3553 episodes were included of which 2553 were historical and 1000 were latest episodes. All cases fulfilled the Sydney classification criteria. According to the laboratory categories, 292 (29.2%) were in category I, 357 (35.7%) in IIa, 224 (22.4%) in IIb and 127 (12.7%) in IIc. Miscarriages were the most prevalent clinical manifestation in 386 cases (38.6%). Moreover, the presence of early preeclampsia (PE) and early foetal growth restriction (FGR) appeared in 181 (18.1%) and 161 (16.1%), respectively. In this series, 448 (44.8%) women received the recommended OAPS treatment. Patients with recommended treatment had a good live-birth rate (85%), but worse results (72.4%) were obtained in patients with any treatment (low-dose aspirin (LDA) or low-molecular-weight heparin (LMWH) not on recommended schedule, while patients with no treatment showed a poor birth rate (49.6%). Conclusion: In this series, recurrent miscarriage is the most frequent poor outcome. To avoid false-negative diagnoses, all laboratory category subsets were needed. OAPS cases have very good foetal-maternal outcomes when treated. Results suggest that we were able to improve our clinical practice to offer better treatment and outcomes to OAPS patients.
Lingua originaleEnglish
pagine (da-a)406-414
RivistaAutoimmunity Reviews
Stato di pubblicazionePubblicato - 2019


  • Antiphospholipid antibody
  • Antiphospholipid syndrome
  • Immunology
  • Immunology and Allergy
  • Obstetric antiphospholipid syndrome
  • Pregnancy autoimmune disorders
  • Registry


Entra nei temi di ricerca di 'The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases'. Insieme formano una fingerprint unica.

Cita questo